Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 3/20 | 0.35 |
| ▸ | SKP1 | P63208 | 3/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.33 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30255015 | 0.87 | KDM4E (0.37) | CKS1BSKP1SKP2OPRK1PIK3CA | |
| SCHEMBL30254917 | 0.86 | OPRK1 (0.36) | CKS1BSKP1SKP2OPRK1 | |
| SCHEMBL20500351 | 0.86 | CKS1B (0.47) | CKS1BSKP1SKP2OPRK1 | |
| SCHEMBL20500375 | 0.74 | CKS1B (0.46) | CKS1BSKP1SKP2OPRK1 | |
| SCHEMBL21810299 | 0.74 | CKS1B (0.46) | CKS1BSKP1SKP2OPRK1 | |
| SCHEMBL16694846 | 0.74 | CYP3A4 (0.39) | CKS1BSKP1SKP2OPRK1PIK3CA | |
| SCHEMBL23658236 | 0.73 | CKS1B (0.46) | CKS1BSKP1SKP2OPRK1 | |
| SCHEMBL20500497 | 0.73 | CKS1B (0.45) | CKS1BSKP1SKP2OPRK1 | |
| SCHEMBL21810232 | 0.73 | CKS1B (0.45) | CKS1BSKP1SKP2OPRK1 | |
| SCHEMBL21248811 | 0.71 | SMPD3 (0.35) | OPRK1FFAR4SMPD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110650951-B | Somatostatin modulators and uses thereof | 克林提克斯医药股份有限公司 | 2023-02-24 | — | — | CN | disclosed |